# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Responses	s)																
Name and Address of Reporting Person*  Roivant Sciences Ltd.				2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X 10% Owner				
(Last) (First) (Middle) SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE				3. Date of Earliest Transaction (Month/Day/Year) 04/16/2020						-	Office	r (give title belo	ow)	Other (specify	below)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person						
)	(State)	(Z	Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)		Date	ite	Execu any	tion Date, i	if Coo	Code (Instr. 8)					Beneficia Reported	cially Owned Following ed Transaction(s)		Ownership Form:	Beneficial	
				(Mont	h/Day/Yea		Code	V	Amoun		or	Price	(Instr. 3	and 4)		or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Stock, \$0 share	.0001 par	04/16/20	020				P		1,034,4	83 A	١.	\$ 14.5	38,439	,450		D	
		7						cor the	ntained in form dis	n this splays of, or	forns a c	n are urren ficially	not requ tly valid	uired to res	spond unle	ess	
2. Conversion or Exercise Price of Derivative Security	Date	Executive (Year) Executive (Year)	A. Deemed secution Day	ate, if	4. Transaction Code	5. Nu of Der Sec Acc (A) Dis of (Ins	mber rivative curities quired ) or sposed (D) str. 3,	6. l and (M	Date Exerc	cisable on Dat	e te	7. Tit Amor Unde Secur	unt of rlying rities	8. Price of Derivative Security (Instr. 5)	Derivative Securities Beneficiall Owned Following Reported	Owners Form o Derivat Securit Direct ( or Indir	Beneficia ive Ownersh (Instr. 4)
	d Address of Sciences L  ), 3RD FLO  E  N, X0 SW  ) ecurity  2. Conversion or Exercise Price of Derivative	Sciences Ltd.  (Street)  N, X0 SW1Y 4LB  (State)  ecurity  Stock, \$0.0001 par  share  Report on a separate line  Conversion or Exercise Price of Derivative  Stock (First)  (Street)  (Street)  (Street)  (Street)  (Street)  (State)  (State)  (Month/Day	d Address of Reporting Person* Sciences Ltd.  (First) (Mi , 3RD FLOOR, 11-12 ST. JA  (Street)  N, X0 SW1Y 4LB  (State) (2. Transa Date (Month/I  Stock, \$0.0001 par share 04/16/2  Report on a separate line for each cl.  Conversion or Exercise Price of Derivative 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	d Address of Reporting Person Sciences Ltd.  (First) (Middle)  3RD FLOOR, 11-12 ST. JAMES'S  (Street)  N, X0 SW1Y 4LB  (State) (Zip)  ecurity 2. Transaction Date (Month/Day/Year)  Stock, \$0.0001 par share 04/16/2020  Report on a separate line for each class of secu  Table II -  2. Conversion or Exercise Price of Derivative 1 Science 1 Security (Month/Day/Year)	d Address of Reporting Person*  Sciences Ltd.  (First) (Middle) (3. D. 04/15 (4. If  N, X0 SW1Y 4LB (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  A Stock, \$0.0001 par Stock, \$0.0001 par Stock (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  2. Table II - Deriv (e.g., 1) (e.g., 1) (Month/Day/Year)	2. Issuer Nam Immunovant Sciences Ltd.  3. Date of Earli 04/16/2020  3. Date of Earli 04/16/2020  4. If Amendme  N, X0 SW1Y 4LB  (State)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Table II - Derivative Secures. (e.g., puts, calls, any (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Date of Earli 04/16/2020  4. If Amendme  Table II - Derivative Secures. (e.g., puts, calls, any (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)	2. Issuer Name and Immunovant, Inc  3. Date of Earliest Tr  04/16/2020  (Street)  4. If Amendment, Da  N, X0 SW1Y 4LB  (State)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Stock, \$0.0001 par od/16/2020  (Instr. 8)  Table II - Derivative Securities beneficially owner of Exercusion Date (Month/Day/Year)  2. Table II - Derivative Securities beneficially owner of Exercusion Date (Month/Day/Year)  (Instr. 8)  2. Table II - Derivative Securities beneficially owner of Exercusion Date (Month/Day/Year)  (Instr. 8)  2. Table II - Derivative Securities beneficially owner of Exercise (Month/Day/Year)  (Instr. 8)  2. Table II - Derivative Securities beneficially owner of Exercise (Instr. 8)  (Instr. 8)  (Instr. 8)	2. Issuer Name and Ticker Immunovant, Inc. [IMV] 3. Date of Earliest Transaction 04/16/2020  (Street) 4. If Amendment, Date Original States (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date, if any (Month/Day/Year) 2. Transaction Date, if any (Month/Day/Year) 2. Transaction Date (Instr. 8)  2. Stock, \$0.0001 par 04/16/2020 P  Report on a separate line for each class of securities beneficially owned direction Date (Month/Day/Year) 3. Date of Earliest Transaction Date of Code (Instr. 8)  2. Table II - No  Code  Table II - Derivative Securities Acquir (e.g., puts, calls, warrants, or Code (Instr. 8)  Transaction Date (Month/Day/Year) 3. Date of Execution Date, if Code (Instr. 8)  Table II - Derivative Securities Acquir (e.g., puts, calls, warrants, or Code (Instr. 8)  Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8)  Table II - Derivative Securities Securities Securities Securities	2. Issuer Name and Ticker or T Immunovant, Inc. [IMVT] 3. Date of Earliest Transaction (Noth/Day/Year)  (Street)  (A. If Amendment, Date Original Inc. (Important of the property of the privative Securities beneficially owned directly on the price of Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (A. Deemed Execution Date, if any (Month/Day/Year)  (Code (Instr. 8)  (Code (Instr. 8)  (A. Deemed Execution Date, if any (Month/Day/Year)  (A. Deemed Execution Date, if any (Month/Day/Year)  (A. Transaction Date (A. Transaction Code (Instr. 8)  (Month/Day/Year)  (Month/Day/Year)	d Address of Reporting Person Sciences Ltd.  2. Issuer Name and Ticker or Trading Sy Immunovant, Inc. [IMVT]  3. Date of Earliest Transaction (Month/Day 04/16/2020  (Street)  3. Date of Earliest Transaction (Month/Day 04/16/2020  4. If Amendment, Date Original Filed(Month N, X0 SW1Y 4LB  2. Transaction Date (Month/Day/Year)  3. Transaction Date (Instr. 8)  4. Table II - Derivative Securities Acquired, Disposed (e.g., puts, calls, warrants, options, conversion of Exercise (Month/Day/Year)  2. Table II - Derivative Securities Acquired, Disposed (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options, conversion of Exercise (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options, conversion of Date (Month/Day/Year)  4. Scourities Derivative Securities Acquired, Disposed (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options, conversion of Date (Month/Day/Year)  4. Scourities Acquired, Disposed (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options, conversion of Date (Month/Day/Year)  4. Scourities Acquired, Disposed (Month/Day/Year)  4. Scourities Acquired (A) or Disposed (Month/Day/Year)  4. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8)	d Address of Reporting Person * Ciciences Ltd.  2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]  3. Date of Earliest Transaction (Month/Day/Year) 04/16/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 04/16/2020  7. Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) Code (Instr. 3) 1. Transaction Date (Instr. 8) 1. Transaction Date (Instr. 8) 1. Transaction Date (Instr. 8) 2. Transaction Date (Instr. 8) 3. Transaction Date (Instr. 8) 2. Transaction Date (Instr. 8) 3. Transaction Date (Instr. 8) 4. Securities Acquired (Instr. 8) 4. Securities Acquired (Instr. 8) 4. Securities Date (Instr. 8) 4. Securities Acquired (Instr. 8) 4. Securities Date (Instr. 8)	Code   V   Amount   Code   Code   V   Amount   Code   Code   V   Code   V   Code   V   Code   V   Code   V   Code   V   Code   Code	d Address of Reporting Person Sciences Ltd.  2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]  3. Date of Earliest Transaction (Month/Day/Year) 04/16/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 04/16/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 04/16/2020  4. If Amendment, Date Original Filed(Month/Day/Year) 04/16/2020  5. Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)  6. Code V Amount (D) Price of Date (e.g., puts, calls, warrants, options, convertible securities)  7. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially Once (Instr. 8) (Instr. 3) (Month/Day/Year) 04/16/2020  8. Stock, \$0.0001 par od/16/2020  9. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially Once (Instr. 8) (Instr.	2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]   Direct Office	Stock   Stoc	Address of Reporting Person* Sciences Ltd.  2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]  3. Date of Earliest Transaction (Month/Day/Year)  04/16/2020  4. If Amendment, Date Original Filed(Month/Day/Year)  04/16/2020  4. If Amendment, Date Original Filed(Month/Day/Year)  05. Relationship of Reporting Person Officer (give title below)  1. Table II - Non-Derivative Securities  1. Table II - Derivative Securities  1. Table II - Derivative Securities  1. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially Owned Geg., puts, calls, warrants, options, convertible Securities  1. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially Owned Geg., puts, calls, warrants, options, convertible Securities  1. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially Owned Geg., puts, calls, warrants, options, convertible Securities  1. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially Owned Geg., puts, calls, warrants, options, convertible Securities  1. Title and Month/Day/Year)  2. Transaction (Check all applic (Check all a	2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]   5. Relationship of Reporting Person(s) to Issue (Check all applicable)   3. Date of Earliest Transaction (Month/Day/Year)   04/16/2020   4. If Amendment, Date Original Filed(Month/Day/Year)   04/16/2020   4. If Amendment, Date Original Filed(Month/Day/Year)   04/16/2020   4. If Amendment, Date Original Filed(Month/Day/Year)   04/16/2020   5. Relationship of Reporting Person(s) to Issue (Check all applicable)   N. X. 195 Omer. Officer (give tilde below)   N. Other (specify)   Other (specify)

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Roivant Sciences Ltd. SUITE 1, 3RD FLOOR 11-12 ST. JAMES'S SQUARE LONDON, X0 SW1Y 4LB		X				

## **Signatures**

/s/ Marianne Romeo Dinsmore, as Authorized Signatory	04/17/2020	
**Signature of Reporting Person	Date	

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.